Potential of Caffeine in Alzheimer’s Disease—A Review of Experimental Studies
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common type of dementia leading to progressive memory loss and cognitive impairment. Considering that pharmacological treatment options for AD are few and not satisfactory, increasing attention is being paid to dietary components that may affect the development of the disease. Such a dietary component may be caffeine contained in coffee, tea or energy drinks. Although epidemiological data suggest that caffeine intake may counteract the development of cognitive impairment, results of those studies are not conclusive. The aim of the present study is to review the existing experimental studies on the efficacy of caffeine against AD and AD-related cognitive impairment, focusing on the proposed protective mechanisms of action. In conclusion, the reports of studies on experimental AD models generally supported the notion that caffeine may exert some beneficial effects in AD. However, further studies are necessary to elucidate the role of caffeine in the effects of its sources on cognition and possibly AD risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“A triple-transgenic mice model of AD (3xTg-AD) is a combination of three mutations resulting in the age-related progressive neuropathy including accumulation of Aβ plaques and NFTs, resulting in the cognitive deficits [98,106,107], whereas the 5xFAD transgenic model concerns five mutations exhibiting severe pathology…”
BackgroundAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 1×
“However, the caffeine doses required to inhibit PDEs and stimulate the RyRs are not achievable in a normal diet and could exert toxic effects in humans [9,23,25,26].”
BackgroundOxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185 · cited 2×
“The most popular hypothesis on the pathogenesis of AD is the amyloid hypothesis, which assumes an important role of Aβ deposits in the form of senile plaques [48,49].”
BackgroundThe cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · cited 1×
“Inflammation-related biomarkers are present in the cerebrospinal fluid, peripheral blood and brain in AD patients [49,53,54].”
BackgroundAlzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551
Behavioral and psychological symptoms of dementia
Cerejeira, J., Lagarto, L., & Mukaetova-Ladinska, E. B. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00073 · Cited by 1,425
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Current understanding of Alzheimer’s disease diagnosis and treatment
Weller, J., & Budson, A. (2018) · F1000Research · doi:10.12688/f1000research.14506.1 · Cited by 1,083 · cited 1×
“These include three drugs from the group of acetylcholinesterase (AChE) inhibitors (donepezil, rivastigmine and galantamine) and memantine, a selective and noncompetitive NMDA receptor antagonist [68,69].”
BackgroundRole of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009
Sex differences in Alzheimer disease — the gateway to precision medicine
for the Women’s Brain Project and the Alzheimer Precision Medicine Initiative, Ferretti, M. T., Iulita, M. F., Cavedo, E., Chiesa, P. A., Schumacher Dimech, A., Santuccione Chadha, A., Baracchi, F., Girouard, H., Misoch, S., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0032-9 · Cited by 1,009
A Review of Caffeine’s Effects on Cognitive, Physical and Occupational Performance
McLellan, T. M., Caldwell, J. A., & Lieberman, H. R. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.09.001 · Cited by 840 · cited 4×
“Adenosine has been shown to reduce the release of various neurotransmitters including glutamate, ACh, dopamine, serotonin and noradrenaline in CNS in experimental models, whereas caffeine, as an adenosine receptor antagonist, to promote the release [22].”
BackgroundInfluentialCoffee consumption and health: umbrella review of meta-analyses of multiple health outcomes
Poole, R., Kennedy, O. J., Roderick, P., Fallowfield, J. A., Hayes, P. C., & Parkes, J. (2017) · BMJ · doi:10.1136/bmj.j5024 · Cited by 835 · cited 1×
“A recent umbrella review of meta-analyses indicated, among others, beneficial role of coffee in reducing risk of type 2 diabetes mellitus (T2D), cardiovascular diseases, some cancers and Parkinson’s disease [15,16].”
BackgroundAlzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810 · cited 6×
“Transgenic technologies allowed mouse and rat models to be created, based on the mutations of APP, presenilin (PS), APOE and tau protein genes [37,42,96].”
BackgroundInfluentialHyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms
Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y., Duff, K., & Davies, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01879.x · Cited by 722
Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Cappelletti, S., Daria, P., Sani, G., & Aromatario, M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666141210215655 · Cited by 631 · cited 5×
“The adverse caffeine effects on the behavior observed at higher doses intake are anxiety, jitteriness and mood disorders [8,13,14,196].”
BackgroundInfluentialScientific Opinion on the safety of caffeine
EFSA Panel on Dietetic Products, N. A. A. (. (2015) · EFSA Journal · doi:10.2903/j.efsa.2015.4102 · Cited by 613
Nutrition and prevention of cognitive impairment
Scarmeas, N., Anastasiou, C. A., & Yannakoulia, M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30338-7 · Cited by 612 · cited 1×
“On the other hand, numerous experimental studies indicated phytochemicals as potentially useful in the prophylaxis of AD, including flavonoids, phenolic acids, carotenoids, curcumin, resveratrol, and some alkaloids (for comprehensive review—see [4,6]).”
BackgroundThe Safety of Ingested Caffeine: A Comprehensive Review
Temple, J. L., Bernard, C., Lipshultz, S. E., Czachor, J. D., Westphal, J. A., & Mestre, M. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00080 · Cited by 557 · cited 3×
“Caffeine intake may negatively affect pregnant women, lactating women, children, adolescents, people with cardiovascular disorders, people with gastric and duodenal ulcer disease and smokers [194,195].”
BackgroundDifferences Between Women and Men in Incidence Rates of Dementia and Alzheimer’s Disease
Beam, C. R., Kaneshiro, C., Jang, J. Y., Reynolds, C. A., Pedersen, N. L., & Gatz, M. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180141 · Cited by 550
Coffee, Caffeine, and Health Outcomes: An Umbrella Review
Grosso, G., Godos, J., Galvano, F., & Giovannucci, E. L. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064941 · Cited by 531 · cited 2×
“A recent umbrella review of meta-analyses indicated, among others, beneficial role of coffee in reducing risk of type 2 diabetes mellitus (T2D), cardiovascular diseases, some cancers and Parkinson’s disease [15,16].”
Backgroundvan Dam, R. M., Hu, F. B., & Willett, W. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1816604 · Cited by 508 · cited 1×
“Caffeine intake may negatively affect pregnant women, lactating women, children, adolescents, people with cardiovascular disorders, people with gastric and duodenal ulcer disease and smokers [194,195].”
BackgroundDanysz, W., & Parsons, C. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02057.x · Cited by 500
Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer’s disease
Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R., & de la Monte, S. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9102 · Cited by 467
Kwon, S.-H., Lee, H.-K., Kim, J.-A., Hong, S.-I., Kim, H.-C., Jo, T.-H., Park, Y.-I., Lee, C.-K., Kim, Y.-B., Lee, S.-Y., et al. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.001 · Cited by 437
Midlife Coffee and Tea Drinking and the Risk of Late-Life Dementia: A Population-Based CAIDE Study
Eskelinen, M. H., Ngandu, T., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0920 · Cited by 428
Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis
Larsson, S. C., Traylor, M., Malik, R., Dichgans, M., Burgess, S., & Markus, H. S. (2017) · BMJ · doi:10.1136/bmj.j5375 · Cited by 382
Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353 · cited 1×
“Multiple potential disease-modifying drug candidates (γ-secretase inhibitors, BACE-1 inhibitors, monoclonal antibodies, anti-Aβ antibodies, tau aggregation inhibitors) failed in the further phases of the trials [36,51,52,171,198,199].”
BackgroundSex differences in Alzheimer's disease and other dementias
Mazure, C. M., & Swendsen, J. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00067-3 · Cited by 350 · cited 1×
“is demonstrated in men, whereas women suffer from more severe symptoms of affective disorders [67].”
BackgroundThe neuroprotective effects of caffeine: A prospective population study (the Three City Study)
Ritchie, K., Carrière, I., de Mendonça, A., Portet, F., Dartigues, J. F., Rouaud, O., Barberger-Gateau, P., & Ancelin, M. L. (2007) · Neurology · doi:10.1212/01.wnl.0000266670.35219.0c · Cited by 347
Oboh, G., Agunloye, O. M., Akinyemi, A. J., Ademiluyi, A. O., & Adefegha, S. A. (2013) · Neurochemical Research · doi:10.1007/s11064-012-0935-6 · Cited by 333
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309
Arendash, G. W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tan, J., Citron, B. A., Lin, X., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1087 · Cited by 308
Mouse models of Alzheimer’s disease
Esquerda-Canals, G., Montoliu-Gaya, L., Güell-Bosch, J., & Villegas, S. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170045 · Cited by 288 · cited 4×
“A triple-transgenic mice model of AD (3xTg-AD) is a combination of three mutations resulting in the age-related progressive neuropathy including accumulation of Aβ plaques and NFTs, resulting in the cognitive deficits [98,106,107], whereas the 5xFAD transgenic model concerns five mutations exhibiting severe pathology…”
BackgroundInfluentialAndrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240
Why do so many clinical trials of therapies for Alzheimer's disease fail?
Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32399-1 · Cited by 228
Rodent models for Alzheimer’s disease drug discovery
Puzzo, D., Gulisano, W., Palmeri, A., & Arancio, O. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1041913 · Cited by 222 · cited 2×
“In the human tau protein (h-tau) transgenic model, the mice tau gene is replaced by the human gene correlating with NFTs development and neurodegeneration [37,42,100,102,103].”
BackgroundThe present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review
Anand, A., Patience, A. A., Sharma, N., & Khurana, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.043 · Cited by 174 · cited 2×
“In fact, the neuropathological hallmarks of AD are the presence of extracellular neuritic plaques, consisting of deposits of Aβ peptides and intraneuronal neurofibrillary tangles (NFTs) composed of aggregated and often truncated, and hyperphosphorylated tau protein [1,50,51].”
BackgroundCoffee Consumption and Cognitive Function among Older Adults
Johnson-Kozlow, M. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf119 · Cited by 173 · cited 1×
“For example, caffeine intake was associated with better cognitive performance in older women, but not in men [202].”
BackgroundLipopolysaccharide-Induced Memory Impairment in Rats: a Model of Alzheimer’s Disease
ZAKARIA, R., WAN YAACOB, W. M. H., OTHMAN, Z., LONG, I., AHMAD, A. H., & AL-RAHBI, B. (2017) · Physiological Research · doi:10.33549/physiolres.933480 · Cited by 167 · cited 2×
“Increased BACE-1 and γ-secretase activity leading to Aβ hippocampal accumulation, elevated proinflammatory cytokines level (IL-1β, IL-6, IL-12, TNF-α), mitochondrial dysfunction, and increased ROS production is observed in LPS-induced model of AD in rats [124].”
BackgroundCaffeine attenuates scopolamine-induced memory impairment in humans
Reidel, W., Hogervorst, E., Leboux, R., Verhey, F., van Praag, H., & Jolles, J. (1995) · Psychopharmacology · doi:10.1007/bf02246090 · Cited by 152 · cited 1×
“Caffeine ameliorated also scopolamine-induced memory impairment in humans [151].”
BackgroundBotton, P. H., Costa, M. S., Ardais, A. P., Mioranzza, S., Souza, D. O., da Rocha, J. B. T., & Porciúncula, L. O. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.034 · Cited by 140 · cited 16×
“Since the main mechanism of caffeine action is associated with a non-selective blockade of adenosine receptors (mainly A1R and A2AR), this problem was undertaken in many studies.”
BackgroundResultInfluentialAnimal models of Alzheimer disease: historical pitfalls and a path forward
Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132 · cited 1×
“The cause of the sporadic forms of AD is unknown; the majority of them develop after 65 years of age [39].”
BackgroundAdvance of sporadic Alzheimer's disease animal models
Zhang, L., Chen, C., Mak, M. S., Lu, J., Wu, Z., Chen, Q., Han, Y., Li, Y., & Pi, R. (2020) · Medicinal Research Reviews · doi:10.1002/med.21624 · Cited by 116
Gao, L., Li, X., Meng, S., Ma, T., Wan, L., & Xu, S. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s235969 · Cited by 115
Caffeine Induces Neurobehavioral Effects through Modulating Neurotransmitters
Alasmari, F. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.02.005 · Cited by 113 · cited 1×
“The blocking of these receptors modulates glutamatergic, cholinergic, dopaminergic, serotoninergic and noradrenergic neurotransmission [8,21,22].”
BackgroundCrude caffeine reduces memory impairment and amyloid β1–42 levels in an Alzheimer’s mouse model
Chu, Y.-F., Chang, W.-H., Black, R. M., Liu, J.-R., Sompol, P., Chen, Y., Wei, H., Zhao, Q., & Cheng, I. H. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.04.148 · Cited by 106
Fukuyama, K., Kakio, S., Nakazawa, Y., Kobata, K., Funakoshi‐Tago, M., Suzuki, T., & Tamura, H. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800238 · Cited by 22 · cited 1×
“by a decrease in BACE-1 expression (which was not associated with caffeine activity) in human neuroblastoma SH-SY5Y cells [184].”
Background
Cited by
Microglia and Alzheimer’s Disease
Merighi, S., Nigro, M., Travagli, A., & Gessi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112990 · Cited by 236
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics
Migliore, L., & Coppedè, F. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00714-w · Cited by 217
Fekete, M., Szarvas, Z., Fazekas-Pongor, V., Feher, A., Csipo, T., Forrai, J., Dosa, N., Peterfi, A., Lehoczki, A., Tarantini, S., et al. (2022) · Nutrients · doi:10.3390/nu15010047 · Cited by 137
Metadata
- Authors
- Londzin, P., Zamora, M., Kąkol, B., Taborek, A., & Folwarczna, J.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2021-02-06
- Volume
- 13
- Issue
- 2
- Pages
- 537
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W3127572766
- Cited by
- 67
- References
- 51
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.